MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancerStephen Johnston, Matthew P. Goetz|npj Breast Cancer|2019Cited by 673
(untitled)Christina Yau, Adam L. Asare, Marie Osdoit et al.|Edinburgh Research Explorer|0Cited by 353
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 studyErica L. Mayer, Michael Gnant, Silvia Antolín et al.|The Lancet Oncology|2021Cited by 255
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancerMothaffar F. Rimawi, Rachel Schiff, Carmine De Angelis et al.|Breast Cancer Research and Treatment|2017Cited by 95
A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i> -Mutant ER-Positive and HER2-Negative Breast CancerX. Cynthia, Matthew J. Ellis, Vera J. Suman et al.|Clinical Cancer Research|2017Cited by 74